M&A Healthcare Advisors (MAHA) is pleased to announce the successful pharmacy sale of Greater Boston Long Term Care Pharmacy, a premier provider of pharmacy services for community-based group homes and assisted living facilities across Massachusetts, to Tarrytown Expocare Pharmacy. Tarrytown Expocare, an Intellectual and Developmental Disabilities (IDD) and Behavioral Health pharmacy provider with operations in 31 states, is supported by Sheridan Capital Partners. This successful pharmacy sale is a strategic acquisition and underscores the value of specialized healthcare services in meeting the evolving needs of underserved populations.

> Read the full press release here

MAHA’s Role in the Transaction

Serving as the exclusive financial and strategic advisor to Greater Boston Long Term Care Pharmacy, MAHA guided the transaction from start to successful pharmacy sale. The deal was led by Mike Moran, Managing Director, and Mike Abud, Senior Associate.

“Working with the Greater Boston Long Term Care Pharmacy team was a privilege. This transaction also marked a significant milestone for MAHA as our first under FINRA registration as broker-dealer agents, a designation we achieved in July of 2024,” said Mike Moran.

Client Testimonial: Trusted Support Through Every Step

“Mike and his team were incredibly supportive throughout the process and worked diligently to bring us together with a buyer who shares our values. I highly recommend Mike and his team if you are considering the sale of your company," said Mike Wessenberg, former CEO of Greater Boston Long Term Care Pharmacy

Overcoming Challenges in Healthcare M&A

Healthcare transactions and successful pharmacy sales often come with unique complexities; this acquisition was no exception. Regulatory approvals, coordination with clinical teams, and ensuring a seamless transition required expert oversight and communication. MAHA played a pivotal role in navigating these challenges, working closely with both parties to facilitate clear communication between leadership and staff, address regulatory requirements efficiently, and build a foundation of trust for long-term collaboration.

With MAHA's guidance, both parties were able to complete a successful transaction that ensures continuity of care for the communities served by Greater Boston Long Term Care Pharmacy while aligning with Tarrytown Expocare Pharmacy’s mission.

About M&A Healthcare Advisors

MAHA is a boutique M&A advisory firm specializing in the lower-middle market healthcare industry. Our mission is to deliver comprehensive, committed support for healthcare businesses navigating the complexities of mergers and acquisitions. Our expertise spans a wide range of healthcare segments, including Behavioral Health, Autism Services, I/DD, Hospice, Home Health, Home Care, Private Duty, Physician Practices, Physical Therapy, Staffing/Medical Recruiting, Facility-Based Care, Labs, Not-for-Profits, and all types of Pharmacy. With a full suite of services—Sell-Side Representation, Expert Valuations, Hourly M&A Consulting, and more—we are proud to empower business owners to achieve their financial and strategic M&A goals.

Partner with MAHA for Your Healthcare M&A Needs

Are you considering selling your healthcare business? MAHA combines industry expertise with personalized support to help you achieve a successful transaction. Contact our team of experts at M&A Healthcare Advisors to learn how we can guide you through every step of the process.

> Read the full press release here

In an article originally reported by Modern Healthcare, UnitedHealth Group and Amedisys continue to assert the advantages of their proposed $3.3 billion merger despite the Department of Justice (DOJ) filing a lawsuit to block the acquisition. UnitedHealth's Optum division recently reaffirmed its commitment to the merger, labeling the DOJ's attempt to prevent it as an overreach that could hinder valuable innovations in home healthcare and hospice services across multiple states. Meanwhile, Amedisys expressed confidence in Optum's case, noting that both companies remain dedicated to advancing their combined capabilities in healthcare.

UnitedHealth and Amedisys Respond

The DOJ argues that merging the two companies could reduce competition in key regions, including parts of the South and Midwest where UnitedHealth's LHC Group and Amedisys both operate. Although Amedisys proposed selling 100 Texas locations to alleviate the DOJ's concerns, the agency remains unconvinced, noting that antitrust issues persist in more than 100 markets, affecting roughly 200,000 patients.

Optum Care Solutions CEO Dr. Patrick Conway reinforced that the Amedisys acquisition would help expand patient access and improve healthcare outcomes through a more coordinated approach to care. "The Amedisys combination with Optum is pro-competitive and will drive further innovation, leading to improved patient outcomes and greater access to quality care," the company stated.

This extended regulatory scrutiny has cast a chill over healthcare mergers and acquisitions, according to Tom Lillis of Stoneridge Partners, a healthcare advisory firm. Lillis noted that the DOJ's lengthy inquiry into this merger may have dampened deal activity within the industry.

Industry Perspective: Optimism Under a New Administration

In light of potential changes with the incoming presidential administration, industry leaders remain optimistic that a more permissive regulatory approach could soon emerge. As Andre Ulloa, founder and managing director at M&A Healthcare Advisors, told Modern Healthcare, he believes the Justice Department under President-elect Trump will be less likely to interfere with mergers and acquisitions in the healthcare space, which could clear the way for future consolidation in home healthcare. Ulloa's perspective suggests that the DOJ's stance on the merger could shift, paving the way for greater flexibility in healthcare consolidation.

With the growing need for post-acute care services for an aging population, this merger would join UnitedHealth Group's resources with Amedisys' expertise to deliver enhanced, patient-centered care. The two companies maintain that their partnership will be a positive step forward, ultimately benefiting patients, healthcare providers, and the industry as a whole.

Read the original article from Modern Healthcare here.

Understanding the 80/20 Rule and Its Implications

The "Ensuring Access to Medicaid Services" rule, finalized on April 22, mandates that home care companies must allocate at least 80% of Medicaid reimbursements directly to caregiver wages. This significant adjustment is poised to reshape the operational strategies of many home care providers.

Industry Consolidation on the Horizon

This regulation could catalyze considerable consolidation within the industry, particularly affecting smaller operators who might find the new financial model unsustainable. With the rule set to take effect in six years, businesses have ample time to strategize; however, the anticipation of increased costs is already influencing long-term decisions.

The Attraction of Home Care in Healthcare M&A

Despite potential challenges, the home care sector remains a highly attractive field for investment. The aging population in the United States is a significant driver, with projections indicating that over 70 million Americans will be 65 or older by 2040, many of whom will prefer to age in place. This demographic trend underscores the growing demand for in-home care services, which include daily living assistance as well as medical care like physical, occupational, and speech therapy as well as wound care.

Strategic Acquisitions and Market Expansion

Larger home care companies and private equity firms are actively seeking acquisition opportunities to expand their reach and enhance their operational scale. This is evident from the actions of companies like Addus HomeCare, whose CEO, Dirk Allison, expressed during a recent earnings call their strategy to acquire additional operations across various states. Allison explained that expanding scale helps spread costs and enhances the capacity for meaningful advocacy with state reimbursement processes.

The Role of M&A Advisors in a Changing Landscape

At M&A Healthcare Advisors, we are committed to supporting our clients through significant transitions like these, providing valuable and timely guidance to ensure they are making informed decisions. Our expertise in navigating the complex terrain of healthcare M&A ensures that our clients can achieve optimal outcomes, whether they are looking to acquire or sell.

Looking Ahead: Opportunities and Challenges

The home care industry's response to the 80/20 rule will likely be multifaceted, involving both challenges and opportunities. Understanding the nuances of these regulations and their long-term implications will be crucial for existing and potential operators. “While these regulatory changes may influence owner's decisions to exit sooner than they were originally planning, we expect valuation trends to remain consist with years prior,” said Mike Moran, Partner and Executive Advisor. As advisors, we are here to provide the insights and support needed to navigate this evolving landscape effectively.

While the 80/20 rule introduces new complexities, it also opens doors for strategic growth and consolidation in the home care industry. At M&A Healthcare Advisors, we remain at the forefront, ready to guide our clients through these pivotal changes with strategic insight and industry expertise.

Read the original article from Modern Healthcare here.